The morbidity of C. difficile in necrotizing pancreatitis

Am J Surg. 2020 Mar;219(3):509-512. doi: 10.1016/j.amjsurg.2019.08.006. Epub 2019 Aug 13.

Abstract

Introduction: Necrotizing pancreatitis (NP) patients commonly require antibiotic treatment during the several month-long disease course. We hypothesized that Clostridium difficile infection (CDI) is common in NP and significantly impacts outcomes.

Materials and methods: Retrospective review of 704 NP patients treated at a single-institution (2005-2018).

Results: 10% (67/704) of patients developed CDI a mean 78 days after NP onset. Patients developing CDI experienced increased total hospital days (CDI, 104; No CDI, 42; P < 0.001), readmission rates (CDI, 85%; No CDI, 64%; P = 0.006), and duration of NP (CDI, 248 days; No CDI, 183; P = 0.001). Risk factors for CDI included antibiotic use (OR, 96.2; 95% CI, 5.9-1556.2; P = 0.001) and any organ failure (OR, 2.0; 95% CI, 1.2-3.3, P = 0.008). Mortality was not affected by CDI (CDI, 10%; No CDI, 9%; P = 0.7).

Conclusion: Clostridium difficile infection is common in necrotizing pancreatitis and negatively impacts morbidity and disease recovery.

Keywords: Antibiotics; Clostridium difficile infection; Colitis; Infectious diarrhea; Necrotizing pancreatitis.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Clostridium Infections / drug therapy
  • Clostridium Infections / epidemiology*
  • Cross Infection / drug therapy
  • Cross Infection / epidemiology*
  • Cross Infection / microbiology*
  • Female
  • Humans
  • Indiana
  • Male
  • Middle Aged
  • Pancreatitis, Acute Necrotizing / drug therapy
  • Pancreatitis, Acute Necrotizing / epidemiology*
  • Pancreatitis, Acute Necrotizing / microbiology*
  • Retrospective Studies

Substances

  • Anti-Bacterial Agents